Adding The KIT Inhibitor Dasatinib (DAS) To Standard Induction and Consolidation Therapy For Newly Diagnosed Patients (pts) With Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Initial Results Of The CALGB 10801 (Alliance) Study
   Google Scholar   
Citation:
Blood vol 122 (21) Abstract 357
Meeting Instance:
ASH 2013
Year:
2013
Type:
Abstract
Sub type:
Poster General
Funding:
NCTN
Endpoint:
Secondary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
Yes
SDC:
No
Parents:
None
Children:
2913  
Program:
TRP
Primary Committee:
Leuk Corr Sci
Sec. Committees:
   
Pharmas:
 
Grants:
 
Corr. Author:
 
Authors:
                           
Networks:
 
Study
CALGB-10801
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords: